Literature DB >> 22192357

14-3-3σ regulation by p53 mediates a chemotherapy response to 5-fluorouracil in MCF-7 breast cancer cells via Akt inactivation.

Guopei Zheng1, Yan Xiong, Sisi Yi, Weijia Zhang, Bo Peng, Qiong Zhang, Zhimin He.   

Abstract

We previously demonstrated that 14-3-3σ was downregulated in 5-fluorouracil (5-Fu)-resistant MCF-7 breast cancer cells (MCF-7/5-Fu). Here, we found that stably enhanced 14-3-3σ expression strengthened the effects of 5-Fu, Mitoxantrone and cDDP. 14-3-3σ stabilised the p53 protein and bound Akt to inhibit its activity and its downstream targets: survivin, Bcl-2 and NF-κB-p50. In addition, decreased p53 expression, but not promoter hypermethylation, was responsible for the downregulation of 14-3-3σ in MCF-7/5-Fu cells. Meanwhile, initial treatments with high concentrations of 5-Fu clearly induced 14-3-3σ and p53 expression in a time-dependent manner. 14-3-3σ-mediated molecular events that synergise with p53 may play important roles in the chemotherapy of breast cancer.
Copyright © 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22192357     DOI: 10.1016/j.febslet.2011.11.034

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  9 in total

1.  iTRAQ-based quantitative proteomic analysis of differentially expressed proteins in chemoresistant nasopharyngeal carcinoma.

Authors:  Kun Wang; Zhen Chen; Lu Long; Ya Tao; Qiong Wu; Manlin Xiang; Yunlai Liang; Xulin Xie; Yuan Jiang; Zhiqiang Xiao; Yahui Yan; Shiyang Qiu; Bin Yi
Journal:  Cancer Biol Ther       Date:  2018-08-01       Impact factor: 4.742

2.  Metformin reverses multidrug resistance and epithelial-mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells.

Authors:  Chen Qu; Weijia Zhang; Guopei Zheng; Zijuan Zhang; Jiang Yin; Zhimin He
Journal:  Mol Cell Biochem       Date:  2013-10-06       Impact factor: 3.396

3.  PAR-5 is a PARty hub in the germline: Multitask proteins in development and disease.

Authors:  David Aristizábal-Corrales; Simo Schwartz; Julián Cerón
Journal:  Worm       Date:  2013-01-01

4.  Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway.

Authors:  B Zhang; B Zhang; X Chen; S Bae; K Singh; M K Washington; P K Datta
Journal:  Br J Cancer       Date:  2014-01-02       Impact factor: 7.640

5.  Loss of the 14-3-3σ is essential for LASP1-mediated colorectal cancer progression via activating PI3K/AKT signaling pathway.

Authors:  Ziyun Shao; Yanjun Cai; Lijun Xu; Xueqing Yao; Jiaolong Shi; Feifei Zhang; Yuhao Luo; Kehong Zheng; Jian Liu; Fengliu Deng; Rui Li; Lanzhi Zhang; Hui Wang; Mingyi Li; Yanqing Ding; Liang Zhao
Journal:  Sci Rep       Date:  2016-05-09       Impact factor: 4.379

6.  The 14-3-3σ/GSK3β/β-catenin/ZEB1 regulatory loop modulates chemo-sensitivity in human tongue cancer.

Authors:  Cong Peng; Xiaoting Jia; Yan Xiong; Jiang Yin; Nan Li; Yingen Deng; Kai Luo; Qiong Zhang; Chengkun Wang; Zhijie Zhang; Guopei Zheng; Zhimin He
Journal:  Oncotarget       Date:  2015-08-21

7.  Microarray-assisted pathway analysis identifies MT1X & NFκB as mediators of TCRP1-associated resistance to cisplatin in oral squamous cell carcinoma.

Authors:  Bo Peng; Yixue Gu; Yan Xiong; Guopei Zheng; Zhimin He
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

8.  14-3-3σ attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.

Authors:  In-Kyu Kim; Sun-Mi Park; Hee Jun Cho; Kyoung Eun Baek; In-Koo Nam; Seung-Ho Park; Ki-Jun Ryu; Jinhyun Ryu; Jungil Choi; Soon-Chan Hong; Jae Won Kim; Chang Won Lee; Sang Soo Kang; Jiyun Yoo
Journal:  Oncotarget       Date:  2013-11

9.  ADAM12-L confers acquired 5-fluorouracil resistance in breast cancer cells.

Authors:  Xuedong Wang; Yueping Wang; Juan Gu; Daoping Zhou; Zhimin He; Xinhui Wang; Soldano Ferrone
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.